OR WAIT null SECS
Bristol-Myers Squibb appointed a new executive vice-president and chief commercial officer from within the company, effective immediately.
On Aug. 28, 2018, Bristol-Myers Squibb (BMS) announced that Christopher Boerner, PhD, has been appointed as executive vice-president and chief commercial officer of the company, effective immediately.
According to BMS, Boerner will lead commercial strategy and execution across all geographies. Boerner will report to Giovanni Caforio, MD, chairman and chief executive officer, and will join the company’s leadership team.
Boerner joined the company in February 2015 as head of the US commercial organization.
Most recently, Boerner was head of international markets at BMS where he was accountable for commercial activities in all ex-US markets. Prior to joining BMS, he served as the executive vice-president of commercial for Seattle Genetics, where he led all commercial activities for the company. Before joining Seattle Genetics, Boerner was with Dendreon Corporation, where he led the marketing team. From 2002 to 2010, he worked at Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including director of marketing on Avastin, director of Avastin franchise strategy, and associate director of oncology market development.
Boerner succeeds Murdo Gordon, who left the company on Aug. 3, 2018, to pursue another opportunity, the company reports.
Source: Bristol-Myers Squibb